Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib.
Van Hest
R M
RM
Schnog
J B
JB
Van't Veer
M B
MB
Cornelissen
J J
JJ
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D002892:Chromosomes, Human, Pair 22 / Q000648:ultrastructure; D002899:Chromosomes, Human, Pair 9 / Q000648:ultrastructure; D003561:Cytarabine / Q000008:administration & dosage; D004347:Drug Interactions; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D002955:Leucovorin / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016066:Pleural Effusion, Malignant / Q000139:chemically induced / Q000737:chemistry; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014178:Translocation, Genetic
D000964:Antimetabolites, Antineoplastic; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D049994:Sodium Potassium Chloride Symporter Inhibitors; D003561:Cytarabine; D005047:Etoposide; D000068877:Imatinib Mesylate; D002955:Leucovorin; D008727:Methotrexate